For an 89-year-old woman with newly diagnosed atrial fibrillation, anxiety and insomnia, who is already taking apixaban (Eliquis) and diltiazem (Cardizem) and has no other medical problems, what is the best medication to treat her nighttime anxiety and insomnia?

Medication for Anxiety and Insomnia in an 89-Year-Old with Atrial Fibrillation

For this 89-year-old woman with newly diagnosed atrial fibrillation already on apixaban and diltiazem, a low-dose benzodiazepine receptor agonist (such as zolpidem 5 mg) or a short-acting benzodiazepine (such as temazepam 7.5 mg) at the lowest available dose is the most appropriate choice for nighttime anxiety and insomnia, with careful monitoring for adverse effects given her age and medication interactions.

Critical Safety Consideration: Diltiazem-Apixaban Interaction

Before addressing the insomnia, it is essential to recognize a significant drug interaction concern:

• Diltiazem substantially increases bleeding risk when combined with apixaban. Recent evidence shows diltiazem use with apixaban is associated with increased serious bleeding compared to metoprolol (rate difference 10.6 per 1000 person-years, HR 1.21), with the risk escalating at diltiazem doses exceeding 120 mg/day (HR 1.29) 1.

• This interaction occurs because diltiazem is a potent inhibitor of CYP3A4 and P-glycoprotein, which are the primary elimination pathways for apixaban, potentially causing overanticoagulation 2, 3.

• Monitor closely for bleeding signs and consider whether rate control could be achieved with metoprolol instead, which does not carry this interaction risk 1, 3.

Pharmacologic Management of Insomnia in Elderly Patients

First-Line Approach

Benzodiazepine receptor agonists (nonbenzodiazepines) are preferred as they have demonstrated efficacy with lower frequency and severity of adverse effects compared to older benzodiazepines 4.

• Start at the lowest available dose given her age of 89 years 4.
• These agents improve sleep quality, increase total sleep time, and decrease nocturnal awakenings 4.
• The melatonin receptor agonist ramelteon is another option with no demonstrated potential for abuse or significant motor/cognitive impairment 4.

Alternative: Short-Acting Benzodiazepines

If benzodiazepine receptor agonists are unavailable or ineffective:

• Use short-acting benzodiazepines at reduced doses for elderly patients 4.
• Estazolam 1-2 mg has shown efficacy in improving sleep latency, total sleep time, and sleep quality 4.
• Avoid long-acting agents like quazepam (half-life concerns with accumulation and daytime impairment) 4.

Critical Geriatric Considerations

Elderly patients face heightened risks that necessitate cautious prescribing:

• Reduced drug clearance due to age-related pharmacokinetic changes increases sensitivity to peak drug effects 4.
• Increased fall risk, cognitive impairment, and daytime sedation are more common in this population 4.
• Dose-dependent and time-dependent impairment requires starting with the lowest dose and monitoring closely 4.

Medications to Avoid

Do NOT use the following for insomnia in this patient:

• Antihistamines, antidepressants (including trazodone), antipsychotics, or anticonvulsants lack systematic evidence for effectiveness in elderly insomnia, and risks outweigh benefits 4.
• Digoxin should not be added for rate control as it is only effective at rest and is a second-line agent 4.

Atrial Fibrillation Management Context

Her current AF management appears appropriate:

• Rate control with chronic anticoagulation is the recommended strategy for most AF patients, including the elderly 4.
• Diltiazem is an appropriate rate control agent (though the interaction with apixaban warrants reassessment) 4.
• Apixaban is appropriate anticoagulation for stroke prevention in AF 4.

Common Pitfalls to Avoid

• Do not use standard adult doses in an 89-year-old; always start at the lowest available dose 4.
• Do not overlook the diltiazem-apixaban bleeding interaction, which significantly increases morbidity risk 1, 3.
• Do not prescribe sedative-hypnotics indefinitely without reassessing need and considering behavioral interventions 4.
• Monitor for paradoxical agitation, confusion, or falls after initiating any sedative medication in elderly patients 4.

Monitoring and Follow-Up

• Assess response within 1-2 weeks of initiating therapy.
• Evaluate for adverse effects including daytime sedation, falls, confusion, or worsening anxiety.
• Monitor INR or bleeding signs given the diltiazem-apixaban interaction 1, 3.
• Consider non-pharmacologic interventions (sleep hygiene, cognitive behavioral therapy for insomnia) as adjuncts or alternatives 4.